A phase Ib dose-escalation study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with bevacizumab with or without paclitaxel in patients with advanced solid tumors.

@article{Naumovski2011API,
  title={A phase Ib dose-escalation study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with bevacizumab with or without paclitaxel in patients with advanced solid tumors.},
  author={Louie Naumovski and Michael S Gordon and Pamela N. Munster and Priti S. Hegde and Jill O Fredrickson and Shuang Bai and Roel Funke and Ilsung Chang and Grace S. Chandler and Daniel S. Chen and Lee S. Rosen},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={2514}
}
2514 Background: Epidermal growth factor-like domain 7 (EGFL7), is a vascular-restricted, tumor selective, extracellular matrix protein that forms perivascular tracks and promotes endothelial cell adhesion and survival, especially under stress. Anti-EGFL7 (MEGF0444A) is a huMAb that inhibits these activities of EGFL7. In combination with an anti-VEGF antibody, anti-EGFL7 significantly enhances the anti-tumor activity of anti-VEGF in multiple murine tumor models. METHODS A standard 3+3 dose… CONTINUE READING